IsoRay – Consensus Indicates Potential -14.7% Downside

Broker Ratings

IsoRay with ticker code (ISR) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 1.6 and 1.25 with a mean TP of 1.45. Now with the previous closing price of 1.7 this would indicate that there is a downside of -14.7%. The day 50 moving average is 1.25 and the 200 moving average now moves to 0.72. The company has a market cap of $141m. Visit the company website at:

Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray was founded in 1998 and is headquartered in Richland, Washington.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index